AIM rule 26
The following information is provided for AIM rule 26 compliance.
Company Secretary: Salim Hamir
Registered address and Head Office:
EKF Diagnostics Holdings plc
Avon House, 19 Stanwell Road, Penarth, Cardiff CF64 2EZ
Country of Incorporation: United Kingdom
Main countries of operation: United Kingdom, Germany, Poland, Russia, USA and China
Company registration number: 04347937
VAT number: 805940921
Date shares admitted for trading: 7th July 2010
Website last updated: 31st October 2016
Exchanges where quoted and traded: EKF Diagnostics securities are not traded on any exchanges or trading platforms other than AIM.
Number of AIM securities in issue: 464,262,781 shares are issued, called up and fully paid. There are currently 27,601,276 unexercised options held by current directors and senior managers at exerciseable price between 15p and 38p and exercisable to May 2025.
Percentage of securities not in public hands: As at 16/06/2016 the percentage of AIM securities not in public hands was: 62.79%.
Restrictions on the transfer of securities: There is no restriction on the transfer of EKF Diagnostics Holdings plc securities.
|Significant shareholders||No. of ordinary shares||% held|
|Zwanziger Family Ventures||31,661,694||6.82%|
|Mr William Pippin||16,189,675||3.49%|
|Nexus Medical Partners||14,096,000||3.04%|
|Shareholder||No. of ordinary shares||% held|
Chief Executive Officer
Chief Operating Officer
*Christopher Mills is partner and Chief Investment officer of Harwood Capital LLP. Harwood Capital LLP is investment manager to North Atlantic Smaller Companies Investment Trust plc and investment adviser to Oryx International Growth Fund Limited. Christopher’s shareholding is made up of 48,650,000 ordinary shares held by North Atlantic Smaller Companies Investment Trust PLC and 35,350,000 ordinary shares are held by Oryx International Growth Fund Limited.
Please click here to view the Annual Report 2015 for EKF Diagnostics Holdings plc